Charles Rosier - Resume - London, UK
Charles Rosier managed the French-speaking markets of France, Belgium, as well as Quebec. There are approximately 2,500 employees employed at BTG Pactual, which has 30 years of experience. Charles Rosier finally became a member of BTG Pactual in August 2010. BTG Pactual is an investment bank in Latin America. Charles Rosier became a partner there.
Charles Rosier and His Work Experiences
At BTG Pactual, Charles Rosier imposed five major values. (Meritocracy and Partnership, World-Class Governance, Client Focus, Global Thinking Presence and Long Term View). He worked as a partner at BTG Pactual, a bank in Latin America, well-known for employing 2,500 staff members all around the world and having 30 years of experience in the international market. GMS (Goldman Sachs) is a leading investment bank that operates around the globe. In his position as their Managing Director, he paid much mind to public asset management. Charles Rosier worked at SBC Warburg as their Debt Capital Manager from the year 1997-2009. But, his first job was as an investment banker at Lehman Brothers.
Innoveox is a French company working with the intention of establishing a friendly and pollution-free environment... with Charles Rosier being its partner. He is devoted to helping the environment by developing energy and power sectors in poor countries. MPOWERD was financed by Charles Rosier to develop lanterns and other energy solutions. They then supplied such to over 25 poor countries around the world.
Programmes in Promoting Culture
At the Venice film festival, a film supported by Charles Rosier and directed by an outstanding Italian screenwriter, won a Silver Lion award. The support he gave to the female French musician is indicative of how greatly he admires culture and music. Charles Rosier played a huge part in a Silver Lion-winning film in the year 2006 and he helped a French musician in producing her debut album in 2012.
Charles Rosier was the major investor of the project, for which a drug was being tested to treat stroke that causes damage to the spinal cord. When Baulieu and his co-workers were experiencing financial difficulties on developing a new drug, he financed them. Because of the capital he provided, the study on depression, strokes and other serious ailments was conducted at Mapreg, a Paris-based medical laboratory.